Aryl-hydrocarbon receptor as a potential target for anticancer therapy

   


1. Koltzov Institute of Developmental Biology of Russian Academy of Sciences, Moscow, Russia
Type: Review
DOI: 10.18097/PBMC20186405397      PubMed Id: 30378556
Year: 2018 vol: 64  issue:5  pages: 397-415
Abstract: Aryl-hydrocarbon receptor (Aryl Hydrocarbon Receptor, AHR) is a ligand-dependent transcription factor, whose functions are related to xenobiotic detoxification, response to inflammation, and maintenance of tissue homeostasis. Recent investigations suggest that AHR also plays an important role in the processes of carcinogenesis. Increased expression of AHR is observed in several types of tumors and tumor cell lines. In addition, it turned out that the composition of pharmaceutical drugs used in oncotherapy includes some ligands AHR. These facts allow us to consider an aryl-hydrocarbon receptor as a potential target for anticancer therapy, especially for the treatment of severe cancers whose treatment options are very limited or do not exist at all. In this review the examples of AHR ligands' effect on tumor cell cultures and on model mice lines with AHR-dependent response are discussed.
Download PDF:
Reference: Vorontsova J.E., Cherezov R.O., Kuzin B.A., Simonova O.B., Aryl-hydrocarbon receptor as a potential target for anticancer therapy, Biomeditsinskaya khimiya, 2018, vol: 64(5), 397-415.
References
 2018(Vol:64)
 2017(Vol:63)
 2016(Vol:62)
 2015(Vol:61)
 2014(Vol:60)
 2013(Vol:59)
 2012(Vol:58)
 In press